Castle Biosciences
Castle Biosciences' revenue rose 3.7% to $344 million in fiscal 2025. Its operating margin was −12.4%, down from 2.6% a year earlier. Free cash flow was $28 million, down 22.5%. The diluted share count fell 0.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Castle Biosciences does
Castle Biosciences runs genetic and molecular tests on patient samples to help doctors decide how to diagnose and treat certain illnesses. Its tests cover skin cancers, Barrett's esophagus (a condition in the food pipe that can lead to cancer), eczema (atopic dermatitis) and eye melanoma. Its customers are the doctors who order the tests.
Its main tests are DecisionDx-Melanoma, which estimates the risk that a melanoma skin cancer will spread or come back, TissueCypher, which estimates the risk that Barrett's esophagus will progress to cancer, and DecisionDx-SCC for another skin cancer. It also sells DecisionDx-UM and MyPath Melanoma. In November 2025 it began a limited launch of AdvanceAD-Tx, a test that helps pick treatment for moderate-to-severe eczema. Castle says about 158 peer-reviewed articles support its tests.
Castle gets paid for its tests by insurers and Medicare, so whether they cover the tests matters a great deal to it. In 2025 it bought a company called Previse, which has technology for collecting esophageal cells without an endoscope, the camera procedure doctors normally use. Castle has lost money in the past.
Its biggest risks, as it describes them
- A large share of its revenue comes from a small number of insurers and other payors.
- Depending mainly on three tests, DecisionDx-Melanoma, TissueCypher and DecisionDx-SCC, for its revenue.
- Medicare coverage decisions for its tests, including reconsideration requests that are still pending.
- Billing for its tests is complex and takes time and resources to collect.
- Past losses, possible need for more capital, and loan terms that limit what it can do.
Income statement
Castle Biosciences lost money in fiscal 2025: a net loss of $24 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 330 | 259 | 243 | 293 | 300 |
| Debt incl. finance leases | 0 | 0 | 0 | 10 | 10 |
| Net debt (negative means net cash) | −329 | −258 | −243 | −283 | −289 |
| Net debt to EBITDA | — | — | — | −11.5x | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −40,079.0x | −4,285.6x | −6,179.7x | 15.0x | −497.8x |
| Current ratio | 14.2x | 8.1x | 6.2x | 7.3x | 5.3x |
| Quick ratio | 14.1x | 8.0x | 6.0x | 7.1x | 5.1x |
Cash flow
Projections
Project Castle Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Castle Biosciences says to expect
- Full year 2026: total revenue
The Company now anticipates generating between $385-395 million in total revenue in 2026, compared to the previously provided guidance of between $365-375 million.
Insider trades
No officer, director or 10% owner of Castle Biosciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 7 of 9 | 4 of 9 |
| Rule of 40 | 51.6% | 62.1% | 11.9% |
| Altman Z'' | 7.63 | 9.07 | 6.15 |
| Accruals ratio | −11.5% | −9.5% | −15.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 4 of 9 | 7 of 9 | 4 of 9 |
Compare
Put Castle Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Castle Biosciences | FY25 | 3.7% | −12.4% | 8.2% | −19.1% | — | 4 | |
| CareDx | FY25 | 13.8% | −8.1% | — | −20.0% | — | 4 | Compare |
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | Compare |
| Schrödinger | FY25 | 23.3% | −65.2% | 4.9% | — | — | — | Compare |
| Starling Oncology | FY25 | 27.8% | −7.2% | −5.5% | −75.7% | — | 3 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 23 | 52 | 63 | 94 | 137 | 220 | 332 | 344 |
| Revenue growth | — | 127.6% | 20.8% | 50.2% | 45.6% | 60.4% | 51.1% | 3.7% |
| Gross profit | 18 | 45 | 53 | 78 | 105 | 175 | 272 | 273 |
| Research and development | 5 | 7 | 13 | 30 | 45 | 54 | 52 | 52 |
| Operating income | −4 | 7 | −6 | −40 | −73 | −68 | 9 | −43 |
| Net income | −6 | 5 | −10 | −31 | −67 | −58 | 18 | −24 |
| Diluted EPS (US$) | −5.33 | −0.21 | −0.54 | −1.24 | −2.58 | −2.14 | 0.62 | −0.83 |
| Diluted shares (millions) | 2 | 9 | 19 | 25 | 26 | 27 | 29 | 29 |
| Cash flow | ||||||||
| Cash from operations | −12 | 7 | 10 | −19 | −42 | −6 | 65 | 64 |
| Capital expenditure | 0 | 1 | 5 | 4 | 6 | 14 | 28 | 36 |
| Free cash flow | −13 | 6 | 5 | −22 | −47 | −19 | 37 | 28 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 27 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 8 | 22 | 36 | 51 | 50 | 46 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 4 | 99 | 410 | 330 | 259 | 243 | 293 | 300 |
| Debt incl. finance leases | 24 | 27 | 0 | 0 | 0 | 0 | 10 | 10 |
| Total assets | 22 | 120 | 439 | 463 | 447 | 453 | 531 | 579 |
| Total liabilities | 32 | 35 | 24 | 51 | 48 | 62 | 75 | 108 |
| Shareholders' equity | −57 | 85 | 416 | 412 | 399 | 391 | 456 | 471 |
| Margins and ratios | ||||||||
| Gross margin | 76.8% | 85.9% | 84.5% | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| Operating margin | −16.8% | 14.1% | −10.4% | −42.6% | −53.2% | −30.9% | 2.6% | −12.4% |
| Net margin | −27.9% | 10.2% | −16.4% | −33.3% | −49.0% | −26.1% | 5.5% | −7.0% |
| Free cash flow margin | −55.2% | 11.7% | 8.2% | −23.9% | −34.5% | −8.8% | 11.0% | 8.2% |
| Rule of 40 (growth + FCF margin) | — | 139.3% | 29.0% | 26.3% | 11.2% | 51.6% | 62.1% | 11.9% |
| Return on capital | — | — | — | — | −51.6% | −37.2% | 4.6% | −19.1% |
| Return on equity | — | 37.0% | −4.1% | −7.6% | −16.6% | −14.5% | 4.3% | −5.2% |
| Return on assets | — | 7.4% | −3.7% | −6.9% | −14.8% | −12.8% | 3.7% | −4.3% |
| Net debt to EBITDA | — | −9.4x | — | — | — | — | −11.5x | — |